Financial Summary
Five Year Financial Summary
Profit & Loss | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
---|---|---|---|---|---|---|
Revenues | A$m | 83.0 | 67.0 | 48.5 | 33.9 | 32.5 |
Expenses | A$m | 37.4 | 32.7 | 22.7 | 22.4 | 14.4 |
Net Profit / (Loss) | A$m | 30.6 | 20.9 | 24.7 | 15.1 | 18.1 |
Balance Sheet | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
Cash & Cash equivalents | A$m | 156.8 | 121.5 | 82.7 | 66.7 | 54.3 |
Total Assets | A$m | 193.0 | 143.9 | 108.6 | 81.5 | 62.3 |
Total Liabilities | A$m | 17.8 | 18.4 | 9.8 | 9.5 | 5.2 |
Equity | A$m | 175.3 | 125.6 | 98.7 | 72.1 | 57.2 |
Cash Flow | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
Cashflow (used in ) operating activities | A$m | 45.0 | 39.9 | 19.3 | 14.2 | 18.4 |
Net increase in cash held | A$m | 40.0 | 37.9 | 16.9 | 11.8 | 17.2 |
Key Variables | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
Basic Earnings per Share | Cents | 60 | 42.3 | 50.0 | 30.6 | 37.6 |
Net Tangible Assets Backing | A$ per share | 2.5 | 2.5 | 1.9 | 1.4 | 1.2 |
Return on Equity | % | 18 | 17 | 25 | 21 | 32 |
Capital raisings
CLINUVEL has raised over A$95.0 million since 2006 to fund its clinical programme for afamelanotide.
Date | Amount Raised A$m |
Shares Issued millions |
Price* A$ |
---|---|---|---|
Sep 2006 Rights Issue and Placement | 35.2 | 9.10 | 3.85 |
Apr 2007 Placements | 26.0 | 2.40 | 10.70 |
Jun 2012 Placements | 6.0 | 3.40 | 1.75 |
May 2013 Placements | 6.3 | 2.98 | 2.14 |
Jun 2014 Placements | 7.2 | 4.17 | 1.67 |
Mar 2016 Placements | 8.3 | 2.53 | 3.30 |
* Represented on post-consolidated basis after capital re-organisation November 2010 (10:1 Reverse Stock Split)